Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus plantarum LP28
- Development stage
- Preclinical
- Lead developer
- Synbio Tech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus plantarum LP28 is a probiotic bacterial strain developed by Synbio Tech Inc. for the treatment of hypersensitivity reactions and allergies. The strain is deposited at the Bioresource Collection and Research Center of Taiwan (BCRC No. 910435) and the China General Microbiological Culture Collection Center (CGMCC No. 3346). It functions as a live biotherapeutic by modulating the host's immune response, specifically by inducing the secretion of regulatory and Th1-type cytokines such as IL-10, TNF-α, IL-12p40, and IFN-gamma, while simultaneously suppressing the Th2-associated cytokine IL-4. LP28 is intended for use in therapeutic medications, functional food products for allergy relief, and as a feed additive for livestock to improve intestinal bacterial balance and immune function.
- Other names
- Lactobacillus plantarum LP28L. plantarum LP28
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))IFNG (Interferon gamma)IL10 (Interleukin-10)IL-4 (Interleukin 4)IL12B (Interleukin-12/23 p40 subunit)
Beyond the preview
Go deeper on lactobacillus plantarum LP28.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus plantarum LP28.